Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
Status:
Not yet recruiting
Trial end date:
2027-01-30
Target enrollment:
Participant gender:
Summary
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5
months postpartum in a randomized placebo controlled trial of bromocriptine therapy to
evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine
prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from
the trial due to a desire to continue breastfeeding but meeting all other entry criteria will
be followed in an observational cohort.